A STUDY OF ATEZOLIZUMAB (MPDL3280A) COMPARED WITH A PLATINUM AGENT (CISPLATIN OR CARBOPLATIN) + (PEMETREXED OR GEMCITABINE) IN PARTICIPANTS WITH STAGE IV NON-SQUAMOUS OR SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC) [IMPOWER110]: